The therapeutic monoclonal antibody market

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of approximate to four new products per year, approximate to 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.